Contra-indicated in patients with hypersensitivity to boron or mannitol.
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Velcade (Millennium)
- INDICATIONS: Multiple myeloma; mantle cell lymphoma
- CLASS: Biologic, Proteasome inhibitor
- HALF-LIFE: 9–15 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Conivaptan, Darunavir, Delavirdine, Efavirenz, Indinavir, Strong CYP3A4 inducers or inhibitors, Telithromycin, Thalidomide, Voriconazole
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of Bortezomib in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 10/11/2024
